Jiangxi Bio (06915) experienced a dramatic "V-shaped" reversal within its first month of trading on the Hong Kong Stock Exchange, swinging from an IPO-day loss and a sharp 60% drop below its offer price to a recent surge past that level.
Listed on June 30, the company, a global leader in the tetanus antitoxin supply chain, saw its stock open at a discount to the HK$11.20 IPO price and close 12.68% lower on its debut. By July 9, the stock had tumbled to a low of HK$3.95, a 64.73% decline from the offer price, marking a challenging start. However, the trend reversed on July 10 with an 11.41% gain, followed by a bullish doji candle. From July 15 onward, the stock rallied strongly, hitting a new high of HK$16.55 on July 28. This represents a 318.99% surge from the July 9 low of HK$3.95 over just 20 days.
Behind the Explosive "Oversold Bounce"
Market attention has recently focused on Jiangxi Bio's strong rebound, but such a move typically follows a period of significant overselling. The stock's decline began before its official listing, during the grey market trading session on June 29. On that day, four new stocks traded, showing extreme divergence. Among them, a healthcare stock surged 177.18% in the grey market, while others saw gains of 38.41% and 7.78%. Jiangxi Bio, however, experienced a volatile ride. Its grey market price initially jumped over 45%, attracting short-term traders, but then plunged as selling pressure emerged, with a maximum intraday loss exceeding 30%. A late recovery trimmed the final loss to just 3.48%.
This poor grey market performance set the tone for the IPO-day breakdown. The June 30 loss meant the stock missed the inclusion window for the Hong Kong Stock Connect program, and combined with the grey market panic, it fell to the HK$3.95 low by July 9. Technically, the Relative Strength Index (RSI) hit a record low of 1.09, and the proportion of profitable positions dropped to just 0.08% on July 8, with daily trading volume falling below 1 million shares. These conditions signaled a shift from extreme divergence to strong consensus among sellers, although the stock's price-to-earnings (PE) ratio of 12.38 times was below the industry average of 21.85 times, setting the stage for a rebound.
What Fueled the 320% Rebound?
Beyond technical and sentiment factors, Jiangxi Bio benefited from a broader sector tailwind in Hong Kong's healthcare sector. Since June, the US dollar has strengthened, rising 2.24% in June, but the increase has been modest, not triggering a sharp rise in US Treasury yields or a global liquidity squeeze. This has shifted investor focus to economic recovery and corporate earnings. Consequently, capital rotation in Hong Kong moved from the hot semiconductor and AI sectors to the previously beaten-down healthcare sector.
Data indicates that since June, multiple Chinese mutual funds, including E Fund, China Asset Management, Fullgoal, and China Universal, have increased their holdings in Hong Kong-listed healthcare stocks. Four such stocks saw fund holdings reach or exceed the 5% disclosure threshold, with some reaching 7%. This trend boosted the Hong Kong biotech index, which has risen over 20% since late June. On July 15, the Hang Seng Biotechnology Index gained over 2% in early trading, with the broader pharmaceutical sector up 4.79%. This market-wide support was a key catalyst for Jiangxi Bio's rebound, which began on that same day. As noted, the stock had fallen 56.70% from its IPO price, and the extreme selling pressure created a strong foundation for the bounce. On July 15, the stock's volume ratio was 1.83, with a turnover of HK$3.138 million, confirming a volume-driven recovery.
By July 28, buying pressure pushed the stock to a new high of HK$16.55, with a sharp acceleration in the afternoon. However, investors should note that the rally on July 28 occurred on declining volume, with 3.43 million shares traded, the second consecutive day of lower volume, compared to 6.02 million shares on July 24. The RSI has surged to 95.07, indicating a shift from oversold to overbought territory. After two weeks of net capital inflows, the stock saw net outflows of HK$3.52 million this week. This divergence between price and volume, along with overbought signals, suggests that the buying momentum may be nearing exhaustion.
Comments